



## GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

February 3, 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--Feb. 3, 2026-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026. Management will host a conference call that day to discuss fourth quarter 2025 financial and operating results at 8:30 a.m. Eastern Time.

### Conference Call Details

Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at <https://ir.genedx.com/>.

### About GeneDx

GeneDx (Nasdaq: WGS) is the global leader in rare disease diagnosis, with a mission to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world's largest rare disease genomic dataset. This unparalleled foundation powers GeneDx's ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device Designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,000 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit [genedx.com](https://www.genedx.com) and connect with us on [LinkedIn](#), [Facebook](#), and [Instagram](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260203915280/en/): <https://www.businesswire.com/news/home/20260203915280/en/>

### Investor Relations Contact:

[Investors@GeneDx.com](mailto:Investors@GeneDx.com)

### Media Contact:

[Press@GeneDx.com](mailto:Press@GeneDx.com)

Source: GeneDx